Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.

Recently, 7 of Viva's portfolio companies have achieved significant results and progress:

• TechnoDerma Completed the Series A+ Funding of Tens of Millions of RMB
• Genhouse Bio was listed on the "2022 Healthcare Venture 50 in the Investment Industry"
• AIxplorerBio Relocated its New Headquarters and Signed a Cooperation Agreement with Xiuzhou District
• QureBio Q-1801 Project was approved by CDE
• VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases
• Arthrosi Announces Positive Topline Results for AR882 Phase 2b Study
• Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors

Keep reading for more details.

TechnoDerma Completed the Series A+ Funding of Tens of Millions of RMB

On January 13, TechnoDerma Medicines Inc. (hereinafter referred to as "TechnoDerma"), incubated and invested by Viva BioInnovator, is an innovation-oriented R&D biotech company focusing on the development of novel small molecule drugs for dermatological diseases. Recently TechnoDerma announced that they have completed the Series A+ funding of tens of millions of RMB. Thanks to the capital market's high recognition of TechnoDerma's Androgenetic Alopecia (AGA) and Atopic Dermatitis (AD) clinical assets, the company has received the support from the Chengdu Biological City No.1 Equity Investment Fund Partnership (L.P.) and Chengdu Hi Tech Investment Developmentin this round of financing.

TDM-105795, a blockbuster small-molecule topical drug for the treatment of AGA, successfully completed the Phase I clinical trial at the end of December 2022, and is expected to start the Phase II clinical trial in mid-March 2023. In addition, TDM-180935, a topical drug for AD, successfully obtained FDA approval for the Phase I clinical trials in August 2022. Currently, the project has officially entered Phase I clinical trials in the United States (Gov. Trial Identifier: NCT05525468).

Genhouse Bio was listed on the "2022 Healthcare Venture 50 in the Investment Industry"

Suzhou, China, January 12, 2023——Genhouse Bio, a biotech company invested and incubated by Viva BioInnovator (VBI), is dedicated to transforming cancer treatment with next-generation small-molecule therapeutics by utilizing integrating technology platform. Recently, they has been ranked in the "2022 Healthcare Venture 50 in the Investment Industry", which is a recognition of Genhouse's continuous innovation capability and R&D strength.

In 2022, Genhouse Bio completed several hundred million RMB Series B financing, and built and improved four new drug R&D centers: Innovation Research Center, Drug Design and Discovery Center, New Drug Screening and Evaluation Center, and Clinical Development Center. The company's core products, GH35, a KRAS G12C inhibitor, and GH21, a SHP2 inhibitor, are rapidly advancing in clinical trials. Recently, GH55, an ERK inhibitor, has successfully obtained the clinical approval in the United States, and completed the first patient dosing in Phase I clinical trial in China. Meanwhile, the more internationally valuable and innovative “Pipeline 2.0” project has also made significant breakthroughs, with several projects expected to file clinical trial applications in 2023.

AIxplorerBio Relocated its New Headquarters and Signed a Cooperation Agreement with Xiuzhou District

January 12, 2023——AIxplorerBio, invested and incubated by Viva BioInnovator (VBI), held new headquarters’ relocation ceremony in Xiuzhou district, Jiaxing. More than 20 guests, including Mr. Yifeng Wang, the member of Standing Committee of the CPC Xiuzhou District Committee and Secretary of the CPC Working Committee of Xiuzhou High Tech Zone, Prof. Bing Su, Professor of Shanghai Jiao Tong University School of Medicine and Director of Shanghai Institute of Immunology, Prof. Yu Tang, Doctoral Supervisor of East China University of Science and Technology, the management team of AIxplorerBio, partners, scientists and investment institutions in various biomedical fields, attended the ceremony and celebrated this milestone together.

In addition, on December 15, 2022, AIxplorerBio and Xiuzhou National High-tech Zone formally signed a cooperation agreement to help the company enter a new stage of development. On the one hand, the signing of this contract has implemented the planned site selection of the office space and biological laboratory of AIxplorerBio in Jiaxing. On the other hand, they will also cooperate to promote open technologies and multi-dimensional products, quickly and high-quality discover and develop innovative drugs in the fields of autoimmune and neurodegenerative diseases, and give full play to the advantages of the integration of drug research and development and AI.

QureBio Q-1801 Project was approved by CDE

QureBio announced that its independently developed Q-1801 project received the domestic CDE clinical trial approval notice on January 11, 2023. Previously, the project had received the FDA clinical approval. Q-1801 was developed by QureBio using its antibody engineering technology platform, which is the world's first bispecific antibody simultaneous targeting SIRPα And PD-L1. Q-1801 is also the second clinical application project of QureBio. So far, QureBio has obtained four IND approvals from China and United States.

VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases

TEL AVIV, Israel and SHANGHAI-- VivaVision, invested and incubated by Viva BioInnovator (VBI), is a pharmaceutical company developing innovative therapies for ocular diseases. Recently, they announced that they are partnering with Everads Therapy, a biotech company developing optimized retinal therapies using its novel suprachoroidal drug delivery technology in order to develop safer, more effective, and more durable treatments for retinal diseases.

The two companies will develop certain undisclosed molecules of VivaVision for suprachoroidal delivery using Everads' technology and expertise. The molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.

Arthrosi Announces Positive Topline Results for AR882 Phase 2b Study

SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company invested and incubated by Viva BioInnovator (VBI), announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors

AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Jan. 5, 2023 /PRNewswire/ -- Triumvira Immunologics, that invested and incubated by Viva BioInnovator is a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. Today they announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Triumvira's ongoing TACTIC-2 trial will evaluate the use of its novel autologous cell therapy TAC01-HER2 as a monotherapy but also in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of HER2-positive solid tumors.

At the European Society for Medical Oncology 2022 Congress, Triumvira presented interim data from the ongoing TACTIC-2 Phase 1/2 trial that demonstrated the safety and preliminary efficacy of TAC01-HER2 in patients with HER2-positive solid tumors regardless of level of expression. TACTIC-2 is actively enrolling participants at five clinical trial sites across the U.S. and Canada. The expansion phase of the trial is expected to launch in 2023. The trial will enroll a monotherapy arm with TAC01-HER2 and a combination therapy arm with TAC01-HER2 and KEYTRUDA, in patients with HER2-positive solid tumors.